Dow Up0.15% Nasdaq Up0.21%

Neogenomics Inc. (NEO)

5.41 0.07(1.28%) Sep 17, 3:59PM EDT
ProfileGet Profile for:
Neogenomics Inc.
12701 Common Wealth Drive
Suite 9
Fort Myers, FL 33913
United States - Map
Phone: 239-768-0600
Fax: 239-690-4237

Index Membership:N/A
Industry:Medical Laboratories & Research
Full Time Employees:315

Business Summary 

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Neogenomics Inc.

Corporate Governance 
Neogenomics Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 4; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Douglas M. VanOort , 59
Exec. Chairman and Chief Exec. Officer
Dr. Michael T. Dent M.D., 51
Founder, Independent Director, Member of Audit Committee, Member of Compensation Committee and Member of Compliance Committee
Mr. George A. Cardoza , 52
Chief Financial Officer
Mr. Steven C. Jones , 51
Chief Compliance Officer, Exec. VP of Fin., Director and Chairman of Compliance Committee
Dr. Maher Albitar M.D., 59
Chief Medical Officer and Director of R&D
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders